Background
Alomfilimab is under investigation in clinical trial NCT03829501 (Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer).• Critical role of activation-inducible lymphocyte immunomediatory molecule/inducible costimulator in the effector function of human T cells: a comparative in vitro study of effects of its blockade and CD28 blockade in human beings and monkeys., PMID:18638655• Identification and characterization of rat AILIM/ICOS, a novel T-cell costimulatory molecule, related to the CD28/CTLA4 family., PMID:11006126• AILIM/ICOS-mediated elongation of activated T cells is regulated by both the PI3-kinase/Akt and Rho family cascade., PMID:17077177• AILIM/ICOS: a novel lymphocyte adhesion molecule., PMID:10607749• AILIM/ICOS signaling induces T-cell migration/polarization of memory/effector T-cells., PMID:15339883• PI3-kinase and MAP-kinase signaling cascades in AILIM/ICOS- and CD28-costimulated T-cells have distinct functions between cell proliferation and IL-10 production., PMID:14550257• JTA-009, a fully human antibody against human AILIM/ICOS, ameliorates graft-vs-host reaction in SCID mice grafted with human PBMCs., PMID:18715691• AILIM/ICOS: its expression and functional analysis with monoclonal antibodies., PMID:11839247• Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL)., PMID:16217039